Atlas Trials

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis

Clinical trial NCT05695950 · COMPLETED

Trial details

NCT number
NCT05695950
Sponsor
Lakefront Biotherapeutics NV
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Dermatomyositis
Start date
2023-02-27
Primary completion
2025-10-13
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.